Wachovia Keeps Outperform on United Therapeutics

Analyst Martin Auster says the company's IV Remodulin was approved one week ahead of schedule

The Food and Drug Administration okayed intravenus use of United Therapeutics' (UTHR ) Remodulin. Wachovia kept its outperform rating on the stock.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.